Fig. 1 | Nature Communications

Fig. 1

From: The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity

Fig. 1

TAC design mimics the TCR-CD3:co-receptor complex. a Left: Naturally occurring TCR-CD3 complex interacts directly with the antigen presented by MHC. Meanwhile, the CD8/CD4 co-receptor interacts with MHC I/II in an antigen-independent manner. Together, these interactions comprise the first step in T cell activation. Right: The TAC receptor re-directs the TCR-CD3 complex towards an antigen of choice using an interchangeable antigen binding moiety (here depicted with an scFv, purple). An scFv is used to recruit the TCR-CD3 complex (blue). Co-receptor properties are incorporated by including the CD4 hinge, TM region, and cytosolic tail (green). b The TAC is incorporated into the pCCL DNA backbone containing a truncated NGFR (tNGFR), which lacks cytosolic signaling domains, as a transduction control. The vector features a bi-directional promoter system with tNGFR under control of the mCMV promoter and TAC expression being driven by the EF-1α promoter. TAC is comprised of an antigen binding ___domain, a CD3-binding ___domain, and a co-receptor ___domain. A variety of proteins can be used for each of these three TAC domains allowing the TAC to be modified to best respond to numerous different antigens. The specific ___domain combinations tested are described below

Back to article page